Since its initial description by Kahlbaum (1828-1899)1 over a century ago, catatonia has been associated with psychiatric, neurologic, and medical disorders. Contemporary authors view catatonia as a syndrome of motor signs in association with disorders of mood, behavior, or thought. Some motor features are classic but infrequent (eg, echopraxia, waxy flexibility) while others are common in psychiatric patients (eg, agitation, withdrawal), becoming significant because of their duration and severity. Catatonia may be subtle and overlooked, which perhaps accounts for former reports suggesting a declining incidence. With renewed recent attention, catatonia is increasingly recognized; several reports of systematic screening in psychiatric admissions find an incidence of 7% to 17%.2
After Kahlbaum, catatonia was associated with schizophrenia by Kraepelin (1855-1925) and Bleuler (1857-1939). This notion continued in the DSM series, despite reports linking catatonia to affective disorders3,4 or systemic/toxic reactions.5,6DSM-IV now recognizes catatonic schizophrenia (295.3x), catatonia due to a general medical condition (293.89), and catatonia secondary to mania or major depression (these lack specific diagnostic codes).
Some authors have advocated a separate nosology for catatonia.7,8 This argument is based on the provisional nature of a diagnosis of catatonia, since it can be associated with metabolic, toxic, neurologic, or psychiatric conditions while appearing similar in features. In addition, the treatment of catatonia is different from that of other major psychiatric disorders. It typically responds well to lorazepam and related benzodiazepines as well as electroconvulsive therapy (ECT), and it may be precipitated or worsened by antipsychotic medications.
A related difficulty of the DSM-IV nosology is that catatonia due to a general medical condition (293.89) is disallowed for an episode that occurs exclusively during the course of a delirium. The DSM requisite of assessing consciousness/attention and cognition is problematic in the usually mute catatonic patient.
Another nosologic debate is whether neuroleptic malignant syndrome (NMS) and serotonin syndrome are forms of malignant catatonia.9,10 These syndromes share many clinical features with catatonia, and recent reports show autonomic disturbances in catatonia, highlighting the clinical overlap. A systematic review of defined NMS cases showed 15 of 16 with catatonia, and severity ratings of NMS correlated with the number of catatonic signs.11 In addition, lorazepam12,13 and ECT14 may treat both catatonia and NMS. The advent of specific rating scales for NMS should allow for systematic research as to its treatment and clinical similarity with catatonia.15,16
The relationship of catatonia to other motor disorders, particularly Parkinson disease, has also been addressed. Two reports found catatonia could be separately identified by divergent scores on parallel ratings of Parkinson disease and catatonia scales in elderly patients with either schizophrenia17 or depression.18 Of note in the latter study, apomorphine improved symptoms of Parkinson disease without affecting catatonic symptoms.
Diagnosis and rating scales
In routine practice, the diagnosis of catatonia can be difficult. Operational definitions for catatonic phenomena have not been well described. In addition, there is debate in the research literature about the number of signs necessary and sufficient to diagnose catatonia, with a range of 1 to 4 signs.19 In DSM-IV, the number of motor signs required to meet criteria for catatonia varies with the primary diagnosis. For catatonia secondary to a general medical condition, only 1 motor sign is needed; for the other diagnoses, 2 signs are required.
DSM-IV does not define these signs well, lacks guidelines about the severity required, and offers a probably incomplete list of signs (only 12 signs are given in the criteria for catatonic schizophrenia). Our group developed a 23-item rating scale (Bush-Francis Catatonia Rating Scale [BFCRS]) that operationally defines each catatonic sign, rates its severity, and provides a standardized schema for clinical examination. A case is defined by the presence of at least 2 of the first 14 items from this scale as shown in the Table.
Screening items from the Bush-Francis Catatonia Scale
(Presence of at least 2 of these 14 signs defines a case)
|*DSM-IV catatonic signs.|
Reliability of the BFCRS depends on the use of its companion standardized examination procedure.19,20 This protocol allows rapid and systematic examination, which facilitates monitoring treatment response, which may occur within hours or less. This scale has been confirmed as highly reliable and sensitive to clinical change.21,22 Other catatonia rating scales have been published and generally correlate well.21,23,24 Although the BFCRS has proved useful and practical for clinical and research purposes, the comparative clinical use of these scales is not well established.
1. Kahlbaum KL. Catatonia. Levi Y, Pridon T, trans. Baltimore, Md: Johns Hopkins University Press; 1973.
2. Caroff S, Mann S, Campbell E, Sullivan K. Epidemiology. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Press; 2004:15-32.
3. Abrams R, Taylor MA. Catatonia: a prospective clinical study. Arch Gen Psych. 1976;33:579-581.
4. Barnes MP, Saunders M, Walls TJ, et al. The syndrome of Karl Ludwig Kahlbaum. J Neurol Neurosurg Psychiatr. 1986;49:991-996.
5. Gelenberg AJ. The catatonic syndrome. Lancet. 1976;2:1339-1341.
6. Wilcox JA, Nasrallah HA. Organic factors in catatonia. Br J Psychiatry. 1986;149:782-784.
7. Benegal V, Hingorani S, Khanna S. Idiopathic catatonia: validity of the concept. Psychopathology. 1993; 26:41-46.
8. Taylor MA, Fink M. Catatonia in psychiatric classification: a home of its own. Am J Psychiatry. 2003; 160:1233-1241.
9. White DA. Catatonia and the neuroleptic malignant syndrome—a single entity? Br J Psychiatry. 1992;161:558-560.
10. Fink M, Taylor MA. Catatonia: A Clinician’s Guide to Diagnosis and Treatment. Cambridge, UK: Cambridge Press; 2003.
11. Koch M, Chandragiri S, Rizvi S, et al. Catatonic signs in neuroleptic malignant syndrome. Compr Psychiatry. 2000;41:73-75.
12. Francis A, Chandragiri S, Rizvi S, et al. Is lorazepam a treatment for neuroleptic malignant syndrome? CNS Spectr. 2000;5:54-57.
13. Khaldarov V. Benzodiazepines as a treatment for neuroleptic malignant syndrome. Hosp Physician. 2000:6:51-55.
14. Petrides G, Divadeenam KM, Bush G, Francis A. Synergism of lorazepam and electroconvulsive therapy in the treatment of catatonia. Biol Psychiatry. 1997; 42:375-381.
15. Sachdev PS. A rating scale for neuroleptic malignant syndrome. Psychiatr Res. 2005;135:249-256.
16. Yacoub A, Francis A. Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam. Neuropsychiatr Dis Treat. In press.
17. Bush G, Petrides G, Francis A. Catatonia and other motor syndromes in a chronically hospitalized psychiatric population. Schizophr Res. 1997;27:83-92.
18. Starkstein SE, Petracca G, Teson A, et al. Catatonia in depression: prevalence, clinical correlates, and validation of a scale. J Neurol Neurosurg Psychiatry. 1996;60:326-332.
19. Bush G, Fink M, Petrides G, et al. Catatonia I: rating scale and standardized examination. Acta Psychiatr Scand. 1996;93:129-136.
20. Bush G, Fink M, Petrides G, et al. Catatonia II: treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand. 1996;93:137-143.
21. Northoff G, Koch A, Wenke A, et al. Catatonia as a psychmotor syndrome: a rating scale and extrapyramidal motor symptoms. Mov Disord. 1999;14: 404-416.
22. Girish K, Gill NS. Electro convulsive therapy in lorazepam non-responsive catatonia. Indian J Psychiatry. 2003;45:21-25.
23. Lund CE, Mortimer AM, McKenna PJ. Motor, volitional and behavioural disorders in schizophrenia. 1: assessment using the Modified Rogers Scale. Br J Psychiatry. 1991;158:323-327.
24. Bräunig P, Kruger S, Shugar G, et al. The catatonia rating scale I—development, reliability, and use. Compr Psychiatry. 2000;41:147-158.
25. Carroll BT, Kennedy JC, Goforth HW. Catatonic signs in medical and psychiatric catatonias. CNS Spectr. 2000;5:66-69.
26. Lopez-Canino A, Francis A. Drug-induced catatonia. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Press; 2004:129-140.
27. Taylor MA, Catatonia: a review of a behavioral neurologic syndrome. Neuropsychiat Neuropsychol Behav Neurol. 1990;3:48-72.
28. Carroll BT, Goforth HW. Medical catatonia. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Press; 2004: 121-128.
29. Stöber G. Genetics. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Press; 2004:173-188.
30. Northoff G. Neuroimaging and neurophysiology. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Press; 2004: 77-92.
31. Carroll BT. GABAa versus GABAb hypothesis of atatonia. Mov Disord. 1999;14:702-703.
32. McCall WV, Shelp FE, McDonald WM. Controlled investigation of the amobarbital interview for catatonic mutism. Am J Psychiatry. 1992;149:202-206.
33. Rosebush P, Mazurek M. Pharmacotherapy. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Press; 2 004:141-150.
34. Wetzel H, Heuser I, Benkert O. Stupor and affective state: alleviation of psychomotor disturbances by lorazepam and recurrence of symptoms after Ro 15-1788. J Nerv Ment Dis. 1987;175:240-242.
35. Lee JWY, Schwartz DI, Hallmayer J. Catatonia in a psychiatric intensive care facility: incidence and response to benzodiazepines. Ann Clin Psychiatry. 2000;12:89-96.
36. Rosebush PL, Hildebrand AM, Furlong BG, Mazurek MF. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry. 1990;51:357-362.
37. Ungvari GS, Chiu HFK, Chow LY, et al. Lorazepam for chronic catatonia: a randomized double-blind, placebo-controlled cross-over study. Psychopharmacology (Berl). 1999;142:393-398.
38. Petrides G, Malur C, Fink M. Convulsive therapy. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Press; 2004:151-160.
39. White DA, Robins AH. Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry. 1991;158:419-421.
40. Hawkins JM, Archer KJ, Strakowski SM, Keck PE. Somatic treatment of catatonia. Int J Psychiatry Med. 1995;25:354-369.
41. Bahro M, Kampf C, Strnad J. Catatonia under medication with risperidone in a 61-year-old patient. Acta Psychiatr Scand. 1999;99:223-224.
42. Carroll BT. The universal field hypothesis of catatonia and neuroleptic malignant syndrome. CNS Spectr. 2000;5:26-33.
43. White DAC, Robins AH. An analysis of 17 catatonic patients diagnosed with neuroleptic malignant syndrome. CNS Spectr. 2000;5:58-65.
44. Van Den Eede F, Van Hecke J, Van Dalfsen A, et al. The use of atypical antipsychotics in the treatment of catatonia. Eur Psychiatry. 2005;20:422-429.
45. Martenyi F, Metcalfe S, Schausberer B, Dossenbach MR. An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms. J Clin Psychiatry. 2001; 62(suppl 2):25-27.
46. Mann SC, Caroff SN, Fricchione GL, et al. Malignant catatonia. In: Caroff SN, Mann SC, Francis A, Fricchione GL, eds. Catatonia: From Psychopathology to Neurobiology. Washington, DC: American Psychiatric Press; 2004:105-120.